Innovative and accredited continuing medical education for today’s practicing clinicians.

CME Institute is trusted by physicians across medical specialties as a source for premium continuing education that yields the highest educational outcomes. These ACCME-accredited CME activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.

  • Expert-led insights to improve patient outcomes
  • Multi-modal courses to suit all learning styles
  • Timely topics for relevant application to practice
  • Innovative formats like vCME

Recent courses

  • Journal
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
Does the capacity to consent vary between medical and psychiatric patients? Are tools needed to assess the patient’s decision-making capacity, or can the provider’s assessment be relied upon? Review the results of a study that sought answers to these questions in this CME journal activity.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Antidepressants
  • Cognition
  • Depression
  • Mood Disorders
What is the efficacy of antidepressants and other agents for treating cognitive impairment in adults with major depressive disorder? Review available research in this CME journal activity.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Self-study / Enduring
  • Diagnostic Tools
  • Sleep
Which patients need evaluation for excessive daytime sleepiness and central hypersomnias? How do the diagnoses of narcolepsy type 1 and type 2 differ? Dr Winkelman shares his expertise in this brief CME activity.
0
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Journal
  • Depression
  • Electroconvulsive Therapy
  • Geriatric Psychiatry
  • Psychotherapy
How many older adults receive electroconvulsive therapy (ECT) for treatment-resistant depression? Among those who receive ECT, how many finish the course? What factors might predict patients’ continuation of ECT? Explore these topics in this journal CME activity.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Adherence
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
In this journal CME activity, find experts’ recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
5
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Depression
  • Medical Conditions
  • Psychotic Disorders
In addition to psychosis, depressive symptoms can occur in patients with anti-NMDAR encephalopathy (ANMDARE). ANDMARE should be considered in patients presenting with psychotic or atypical depressive illnesses. Early recognition of ANMDARE could lead to better management of this potentially life-threatening autoimmune disorder.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Depression
  • Obsessive-Compulsive and Related Disorders
First-line treatments for OCD include selective serotonin reuptake inhibitors and cognitive-behavioral therapy. But what do you do when patients do not respond to these or second-line strategies? In this journal CME activity, explore the option of deep brain stimulation.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this journal CME activity that describes expert consensus.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Self-study / Enduring
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • Primary Care
Learn from experts in neurology, psychiatry, neuropsychology, and primary care about working with patients and care partners to create management plans for Alzheimer’s disease that ensure safety, optimize patient autonomy, and minimize agitation and conflict.
0
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation

Pages

My Courses

Please login or create an account to view your activities.

Transcript

Please login or create an account to view your activities.